Novartis | NOVN - Ebitda


Novartis reported $8.62B in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Alcon AG USD 800M 5M Jun/2026
Almirall EUR 80.45M 33.61M Jun/2026
Amgen USD 5.8B 1.25B Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Autolus Therapeutics Ltd USD -56.8M 13.28M Mar/2026
Bayer EUR 1.62B 529M Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Fresenius EUR 912M 76M Sep/2026
Fresenius Medical Care EUR 817M 26.66M Sep/2026
Genmab DKK 401M 186M Jun/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
GRIFOLS EUR 505M 32M Sep/2026
Hikma Pharmaceutical USD 369M 84M Dec/2024
J&J USD 8.99B 721M Jun/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.6B 69M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Novartis USD 5.36B 45M Sep/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Orion EUR 225.5M 33.6M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Philips EUR 772M 138M Sep/2026
Recordati EUR 256.6M 26.98M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
UCB EUR 1.6B 570M Dec/2025